The role of immunotherapy is supported by the evidence that immune-checkpoint inhibitors are more effective in KRAS mutated NSCLC, and this combination represents an interesting therapeutic strategy as well as combination with several other targeted therapies [72]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.